Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →In a retrospective cross-sectional genomic-profiling cohort of 3,533 pediatric patients with non-MSI-H solid tumors, TMB-H prevalence was 1.42%, was higher among patients aged 12–17 years, and remained below 3% across evaluated tumor-type subgroups.
The study establishes that a small subset of pediatric non-MSI-H solid tumors meet a TMB-H threshold associated with pembrolizumab response in prior studies; it is therefore reasonable—but untested in this record—to hypothesize that TMB testing could identify rare pediatric patients for prospective evaluation of immune-checkpoint therapy.
Primary fibroblasts from 136 childhood cancer survivors, unlike those from 68 matched cancer-free individuals, showed efficient resolution of residual γH2AX foci after very-low-dose irradiation, while repair responses at higher doses were similar between groups.
The evidence supports an altered low-dose DNA-damage response in fibroblasts from childhood cancer survivors; it remains an inference that this phenotype reflects inherited or treatment-acquired alterations and could eventually serve as a biomarker for radiation-risk stratification, surveillance, or treatment planning.
In a retrospective single-center cohort of predominantly adult patients with chronic HCV, DAA therapy produced high SVR12 rates across HCC-history groups and was associated with preserved, but not improved, liver functional reserve after non-curative HCC treatment.
Evidence: DAA therapy achieved a 96.1% overall SVR12 rate, with similarly high responses after non-curative HCC treatment, while measured liver functional reserve remained stable and did not differ by early versus delayed initiation. Inference: HCV eradication could serve as a supportive strategy to preserve hepatic treatment capacity in selected patients receiving non-curative HCC therapy, but causal benefit, safety, survival impact, and pediatric applicability are not established.
The paper reports a GDPR-aligned, distributed infrastructure using EUPID privacy-preserving record linkage to integrate clinical, biological, and imaging data from more than 700 European neuroblastoma patients for AI model development within PRIMAGE.
Evidence: the infrastructure linked pseudonymized multimodal patient data and supported AI models intended to predict clinical outcomes; inference: if those models are independently validated and prospectively shown to improve decisions, the platform could support risk stratification or treatment selection, but no therapeutic benefit or clinical utility is demonstrated here.
This mixed-methods implementation evaluation reports that a medical-society train-the-trainer program reached 18,206 Indian physicians and was associated with more favorable post-training HPV vaccine knowledge, confidence, beliefs, and intent, alongside generally consistent delivery and plans for continuation.
The record supports the feasibility and broad reach of physician training, while it remains an inference—not demonstrated here—that improved physician recommendation capacity will increase HPV vaccination uptake among children and ultimately reduce HPV-related cancer incidence and mortality.
This preregistered meta-analysis of 174 studies involving 92,548 children found small elevations in internalizing, externalizing, and total behavioral problems among children of parents with chronic physical health conditions, with the weakest elevations reported in families affected by parental cancer.
The evidence supports screening children of chronically ill parents for emotional and behavioral difficulties; it is reasonable but untested to infer that targeted prevention or psychosocial intervention could improve outcomes, and the supplied record does not establish efficacy specifically in pediatric-oncology-related families.
In 135 children and controls, preoperative perceptual speech assessment found that children with posterior fossa tumours who later developed postoperative speech impairment had greater resonance and voice-quality abnormalities than tumour patients who retained habitual speech.
The observational findings support preoperative speech abnormalities as candidate risk markers for postoperative speech impairment; it remains an untested inference that using these markers for risk stratification or targeted speech prehabilitation would reduce severity, duration, or long-term consequences.
The study developed a semi-solid-extrusion 3D-printed orodispersible film containing nanostructured-lipid-carrier-encapsulated pimavanserin and celecoxib, with infill density controlling film disintegration, swelling, and pimavanserin release.
The record demonstrates a customizable pharmaceutical delivery platform, not anticancer activity; it is reasonable to hypothesize that infill-adjusted films could enable age-appropriate, individualized dosing of these repurposed drugs in pediatric oncology, but efficacy, safety, pharmacokinetics, palatability, and clinical feasibility remain untested in the supplied evidence.
In 1,305 patients from three centers, a T2-weighted MRI deep-learning pipeline achieved high tumor-segmentation Dice scores, moderately high accuracy for distinguishing medulloblastoma, ependymoma, and pilocytic astrocytoma, and lower but potentially useful accuracy for medulloblastoma and ependymoma molecular subtyping.
The record demonstrates noninvasive tumor classification and molecular-subtyping performance, not improved treatment outcomes; if prospectively validated in clinical workflows, this pipeline could support earlier treatment planning, biopsy targeting, or prioritization of confirmatory molecular testing, but therapeutic benefit remains inferential.
This scoping review identified 10 studies describing eight resources for disclosing hereditary tumor risk to children and adolescents, finding limited empirical evaluation and inconsistent inclusion of psychosocial support.
The review provides evidence that developmentally tailored disclosure resources exist but are sparsely evaluated; it is reasonable, but not demonstrated here, to hypothesize that structured decision-support or bibliotherapy-based interventions could improve family communication, informed surveillance, and uptake of preventive measures.
In a retrospective pooled analysis of 299 predominantly adult MEITL patients, advanced stage, non-ileal-only involvement, elevated LDH, and poor treatment response were associated with worse survival, while the apparent survival advantage of stem cell transplantation weakened after accounting for transplant timing.
The record provides exploratory evidence that chemotherapy-sensitive patients may be the subgroup most likely to benefit from stem cell transplantation; prospectively validating response-adapted transplantation and the proposed risk factors could improve treatment selection, but a causal benefit and applicability to pediatric patients are not established.
In a single-centre cross-sectional cohort of 117 children with unilateral non-syndromic Wilms tumour, isotopic GFR, albuminuria testing, and ambulatory blood pressure monitoring identified renal abnormalities that were frequently not captured by creatinine-based eGFR, despite common contralateral compensatory hypertrophy.
The study provides evidence that multimodal renal surveillance can detect otherwise silent dysfunction in Wilms tumour survivors; it is reasonable but unproven to infer that earlier identification could enable nephroprotective monitoring or intervention and reduce later renal morbidity.
